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Abstract  
Many questions about the long-term effects of combination antiretroviral therapy (cART) on 
clinical outcomes in people living with HIV (PLWH) and their impact on health systems 
remain unanswered. The Collaboration of Observational HIV Epidemiological Research 
Europe (COHERE) was formed in 2005 to pool and harmonize existing longitudinal data on 
people living with HIV in Europe, to answer key research questions that could not be 
addressed adequately by individual cohorts.  Key research questions include long-term 
prognosis, rare outcomes, and variations across patient groups, settings and health systems. 
COHERE uses the HIV Cohorts Data Exchange Protocol, a standardized and validated 
method of data structure and transfer, to compile data from over 40 cohorts of PLWH 
residing in Europe, representing 331 481 individuals, including 2808 children (<13), 
representing 2 135 896 person-years of follow-up. COHERE compiles data on clinical 
characteristics, antiretroviral therapy and other medications, estimated date of HIV 
seroconversion, opportunistic infections, laboratory results and socio demographic data. 
External collaborators interested in conducting a project in COHERE should submit a project 
proposal to the Regional Coordinating Centres in Bordeaux and Copenhagen for review by 
COHERE’s governing bodies (see www.cohere.org for further information). 
 
Key Messages:  
• COHERE adds value by focusing on questions that cannot be addressed by single 
cohorts because of sample size requirements, ensuring the sustainability of individual 
cohorts. 
• Recent and exemplary reports by COHERE suggest that earlier and more widespread 
testing for HIV with linkage to care was required to reduce the incidence of late 
presentation. 
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• Non-injection drug users living with HIV with CD4 cell counts above 500/mm3 after 
starting cART had mortality patterns similar to those in the general population.  
• COHERE has informed models of HIV progression and the effect of therapy which 
have been used to characterize HIV-infected populations, inform public health policy 
and serve as a basis for cost-effectiveness analysis. 
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Why was COHERE set up?  
Widespread access to effective combination antiretroviral therapy (cART), beginning in 1996, 
dramatically reduced the number of AIDS-related events and deaths in people living with HIV 
(PLWH) in high-income settings.1 The study of prognosis and specific clinical outcomes 
therefore requires larger populations. The Collaboration of Observational HIV 
Epidemiological Research Europe (COHERE) was founded in 2005 to continue to advance 
epidemiological research on the prognosis of PLWH in Europe. COHERE has expanded and 
strengthened collaborative efforts in Europe and facilitated those with other regions by 
ensuring that longitudinal data, the product of early investments in clinic-based databases 
and observational studies, were compiled and harmonized. In 2011, COHERE joined three 
other European HIV collaborations, PENTA, EuroSIDA, and CASCADE to form “EuroCoord”, 
a Network of Excellence funded by the European Commission Seventh Framework 
Programme.2 COHERE also collaborates with the ART Cohort Collaboration (ART-CC) and 
the International Epidemiologic Databases to Evaluate AIDS (IeDEA) global network.3, 4 
How does COHERE operate?  
COHERE operates according to the principles set out in Box 1. Projects in COHERE provide 
added value by only addressing scientific questions that cannot be answered by participating 
cohorts.  
Two Regional Coordinating Centres (RCCs), based at the University of Bordeaux’s Institut de 
Santé Publique, d'Épidémiologie et de Développement (ISPED) in Bordeaux, France and the 
Center for Health and Infectious Diseases Research (CHIP), Department of Infectious 
Diseases and Rheumatology, Rigshospitalet, in Copenhagen, Denmark, maintain COHERE’s 
infrastructure. The COHERE Steering Committee (SC) -- composed of representatives from 
the participating cohorts -- oversees the COHERE Collaboration, ensuring compliance with 
its principles; it also elects the Chair and the “Regional Representatives” to the COHERE 
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Executive Committee (EC). The EC -- composed of three representatives from each of the 
two regions, and the two RCC Heads -- acts as the functional link between the RCCs and the 
SC.  
COHERE projects are organized by “themes” (Prognosis and the effect of antiretroviral 
therapy (ART), Hepatitis, Opportunistic Infections, Malignancies, Late Presentation, and 
Socio-economic Inequalities) to encourage collaboration and streamline the project proposal 
process. Theme Leads stimulate scientific enquiry within their theme and develop projects. A 
detailed account of how COHERE operates is described in the Manual of Operations 
(www.cohere.org).   
Who participates in COHERE? 
COHERE has grown from 33 cohorts in 2005 to 40 in 2015. COHERE initially approached 
cohorts because of their proven ability to address scientific questions and collect good quality 
data at clinical sites. As COHERE is a project-based collaboration, the data pooled in annual 
mergers depend on the projects included. Western European countries with longstanding 
national cohorts contribute a large proportion of person-years of follow-up, but there is  an 
increasing number of individuals in care in Eastern Europe, primarily via the EuroSIDA 
network.5 Figure 1 presents the number of people living with HIV (excluding deaths) included 
in COHERE as of 31/12/2011 as a percentage of UNAIDS 2011 estimates of people living 
with HIV by country.  
COHERE includes both clinic/hospital-based cohorts of HIV-infected individuals, where data 
are extracted primarily from medical records in the context of routine care, and interval 
cohorts of specific populations of HIV-infected people, where data are collected at regular 
intervals that are unrelated to participants ongoing health care. Since people with HIV are 
seen regularly over a long period of time at a clinic/hospital, and are not just attending at 
times when they are symptomatic, the group of people seen at a given hospital naturally 
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forms a cohort. Table 1a and 1b present a complete list of the cohorts, their characteristics 
and funding sources. All COHERE cohorts follow local ethical standards.  
The 2014 merger included data from 331 481, including 2,808 children (<13), representing 
2 135 896 person-years of follow-up. Table 2a highlights the demographic characteristics 
and prognostic markers of HIV in those aged 13 and older enrolled in adult cohorts. 
Approximately a quarter of the COHERE sample is female (27%). The median age at 
inclusion is 35 [IQR: 30, 43]. The primary mode of HIV transmission is sexual contact 
[homosexual/bisexual contact (38.7%), heterosexual contact (37%)], followed by injection 
drug use (IDU) (13.5%). Overall, 71.6% of the sample has never had a clinical AIDS 
diagnosis before or during enrolment. The median CD4 cell count at enrolment, defined as 
the period six months prior to and one month after enrolment date, was 340 cells/mm3 [IQR: 
170, 530] in adults (Table 2a).  Of those with an available CD4 cell counts at enrolment, 29% 
had <200 cells/mm3, 22% had between 200 and 350 cells/mm3, and 49% had >350 
cells/mm3. Of those younger than age 13 (N=2808, representing 23 458), 93.7% were 
infected via vertical transmission and 73.4% had never had an AIDS diagnosis (Table 2b).  
How often have they been followed up?  
As a consortium of cohorts comprising clinic and interval cohorts, patient follow-up varies. 
For clinic or hospital-based cohorts, average patient follow-up reflects current standards of 
care in those countries.  
A derived measure of lost to follow-up (LTFU) was constructed by estimating the median last 
clinical encounter (defined as either visit and/or the date of last laboratory test) per active 
cohort. Those individuals who had not had a clinical encounter in the 18-months prior to this 
date were considered to be LTFU.  Those who died during the same period were excluded.  
On average, 25% of the COHERE 2014 sample met this definition of LTFU, with variation 
between cohorts.  LTFU in paediatric cohorts was estimated among those under age 17 as 
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many cohorts discontinue follow-up at age 18.  LTFU among paediatric patients aged <17 (N 
= 1,960) was 20% overall and ranged from 1.8-22% across cohorts. 
What data are collected and how?  
COHERE has benefited from dynamic data management processes, which have evolved to 
accommodate new projects and scientific questions. COHERE’s Data Managers (DMs) work 
with Project Leads and Statisticians to conduct preliminary surveys, feasibility studies and, 
occasionally, collect additional data. COHERE collects data on basic clinical information 
including: date of first HIV positive test, estimated date of seroconversion, cART and other 
medications, opportunistic infections, and laboratory results (CD4, CD8, plasma viral load 
values, hepatitis B and C serological tests, and HIV drug resistance tests), as well as socio-
demographic data (see www.hicdep.org for more information about the definition of different 
variables). COHERE, via EuroCoord, conducts an inventory of data items and biological 
samples collected by participating cohorts. The submission of data to COHERE is facilitated 
by the use of the HIV Cohorts Data Exchange Protocol (HICDEP), a flexible data structure, 
developed in 2004, to guide the mapping of individual cohort data into a standard format to 
facilitate data merging.6   
For approved projects, COHERE DMs organize data collection by developing a standardized 
operating procedure (SOP) for individual cohort DMs. Data are submitted in two stages via 
the HIV-Distributed Data Management (HIV-DDM) Tool.7  This implies that data submissions 
must therefore pass all format and edit checks, defined in HICDEP, before the submission 
can be completed. Additional inconsistencies are identified centrally.  Cohorts are given an 8-
week window to address said data inconsistencies before completing the second and final 
submission. Once data are merged, likely duplicate patient records between and within 
cohorts are identified using probability linkage. Data items used are gender, year of birth, 
treatment history, viral load measurements and CD4 cell counts. Duplicate records are 
reconciled based on prior agreements between participating cohorts. DMs identified and 
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resolved 20,953 duplicate records in 2014. Cohorts resolve issues identified over time, 
ultimately improving data quality with each merger.  To ensure transparency, the content of 
each merger together with cohort’s QA check feedback is summarized in a report. DMs 
extract data for projects based on specified and agreed eligibility criteria. After signing a data 
protection agreement, project leads are sent data extractions in a secure format.  
What has been found?  
Projects within the COHERE collaboration have led to the publication of 28 articles in peer-
reviewed journals as of April, 2016, contributing high-quality evidence that has informed 
clinical and public health decision-making.  
Prognosis and the effect of ART  
The “Prognosis and the effect of ART” group focuses on clinical outcomes in patients treated 
with cART. The effect of age on the response to cART was studied in around 50,000 
antiretroviral-naive individuals. Older individuals were characterized by low pre-ART CD4 cell 
counts, and experienced poorer immunological responses but better virologic responses, 
indicating those who are diagnosed or treated late are at increased risk of clinical events.8  
Non-IDU HIV-infected individuals who achieved high CD4 cell counts after starting cART 
were found to have mortality patterns similar to those in the general population. Mortality was 
found to be persistently higher in individuals with a prior AIDS diagnosis 9, while the 
incidence of AIDS events continued to decline until CD4 cell counts were greater than 750 
cells/mm3.10 In patients with viral suppression, the risk of a new AIDS events or death 
followed a CD4 cell count gradient, even benefiting those with a CD4 cell count ≥500 
cells/mm3.11 Individuals who were virally suppressed on cART for more than three years but 
had incomplete CD4 cell recovery experienced substantially higher rates of mortality from 
both AIDS and non-AIDS causes, suggesting that these individuals should be monitored for 
diseases not conventionally considered HIV-related, especially non-AIDS defining cancers 
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and liver diseases.12 Future research will focus on new markers of the risk of morbidity and 
cause-specific mortality, outcomes in individuals treated for many years, and outcomes in 
people aging with HIV, particularly in the context of multi-morbidity and polypharmacy. 
The COHERE’s Pursuing Later Treatment Options (PLATO) II project looked at the rate of 
development of virologic failure in adults, adolescents and children. When virologic failure 
has occurred with at least two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), 
a non-nucleoside reverse transcriptase inhibitor (NNRTI) and a ritonavir-boosted protease 
inhibitor (PI), patients are said to have experienced triple class virologic failure (TCVF). 
Fewer than 9% of adult patients had experienced TCVF at year nine after starting cART.13 
The risk of TCVF was somewhat higher in children and particularly higher in adolescents.14 
Virologic suppression after TCVF was found to have increased from 20% in 2000 to 58% in 
2009. Rates of AIDS and death also declined over time in people with TCVF.15 The incidence 
of TCVF in people on cART declined after 2008, and prevalence stabilized at around 2.5%.16 
An approximately linear inverse relationship between log10 viral load and CD4 cell count in 
people with TCVF points to likely immunologic benefits of reducing viral load, even by 
modest amounts, without necessarily resulting in an undetectable viral load.17 
Late Presentation 
Late presentation is defined as an HIV-diagnosis with a CD4 cell count <350/mm3 or an AIDS 
diagnosis, regardless of CD4 cell count, within six months of HIV-diagnosis. This definition 
was applied to 84,524 PLWH presenting for care between January 1st, 2000 and June 30Th 
2011 in Europe. Late presentation was present in over half (53.8%) of the sample. It 
decreased over time in both Central and Northern Europe among homosexual men and 
heterosexuals, but, in contrast, increased over time in Southern Europe among female 
heterosexuals and male IDUs and in Eastern Europe among IDUs. Late presentation was 
associated with increased mortality, especially in the first year after diagnosis, with significant 
variation across Europe.18 Further analyses study changes in late presentation within 
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different regions and demographic groups since 2010.19 These findings have provided 
comprehensive evidence of patterns in late presentation in Europe and have informed 
discussions around earlier and more widespread testing for HIV and linkage to HIV care.20    
Opportunistic Infections 
Thirty per cent of HIV infected people either present late with an OI or are at significant risk 
of an OI.18 The COHERE OI group has described both the spectrum and incidence of OIs in 
patients on cART with high CD4 cell counts.10, 11 By including viral suppression as a cofactor, 
it was found that Pneumocystis jirovecii prophylaxis could safely be stopped in an additional 
40% of patients when compared with guidelines based exclusively on CD4 cell counts,21 
findings which informed both the American and European treatment guidelines 22, 23. The 
group is conducting similar analyses for toxoplasmosis and other OIs and intends to 
reassess the guidelines on the timing for discontinuing secondary prophylaxes against 
specific OIs. 
While the early start of cART in the course of cryptococcal meningitis has been shown to be 
harmful in some clinical trials performed in resource-limited settings24, 25, in Western settings 
with advanced clinical monitoring this may not be the case.26 Current COHERE projects are 
examining the effect on mortality of the time of cART initiation after a diagnosis of 
cryptococcal meningitis or Toxoplasma gondii encephalitis. Preliminary results from a 
COHERE, NA-ACCORD and CNICS collaboration have shown that early cART did not 
increase mortality in AIDS patients with cryptococcal meningitis in high-income countries and 
overall mortality was lower than that reported by the clinical trials conducted in Africa.27 
Current analyses explore how specific OIs influence long-term immune reconstitution, 
morbidity and mortality in the most recent cART era.  
Malignancy 
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The COHERE malignancy group has focused on defining the incidence, risk factors and 
prognosis of HIV-associated cancers in the cART era, with a focus on systemic non-Hodgkin 
lymphoma (NHL) and primary brain lymphoma (PBL), Hodgkin’s lymphoma and, more 
recently, Kaposi’s sarcoma.28-30 The incidence of non-Hodgkin’s lymphoma, primary brain 
lymphoma and Kaposi’s sarcoma were substantially reduced in patients on cART, and timely 
initiation of therapy at high CD4 cell counts is important for preventing these malignancies.28, 
30 In contrast, the incidence of Hodgkin’s lymphoma was not reduced by cART. Patients 
whose CD4 cell counts declined despite suppression of HIV-1 replication on cART were at 
increased risk of Hodgkin’s lymphoma.29 Comparative analyses are planned in collaboration 
with the African regions of IeDEA.4 
Hepatitis  
The immunological changes over the course of HCV treatment and their effect on mortality 
were estimated in 6,433 HIV-HCV-co-infected adults (≥16), 12% of whom had initiated HCV 
treatment (n=692 interferon and ribavirin; n=88 interferon alone). 31 CD4 cell counts 
decreased over the first 12 weeks but stabilized from week 24 onwards with no negative 
impact on mortality. The group is poised to monitor the effect of the introduction of direct-
acting antiviral agents in co-infected patients.  
Socio-economic inequalities  
The Socio-economic inequalities group studies differences in key outcomes by sex, 
race/ethnicity, migrant status and educational level as a proxy for socioeconomic position. 
Even in European countries with universal health care systems, it has been documented that 
individuals with lower educational level do not benefit equally from timely cART initiation and 
have a poorer response to cART.32  
Mortality in migrants has been found to be lower compared to native populations, which has 
been attributed to the “healthy migrant effect”. COHERE’s larger sample size has allowed 
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this group to study mortality in men and women from multiple geographical origins 
separately, highlighting heterogeneity among migrant groups and revealing how certain 
groups are at an increased risk of mortality 33, work which was featured in the first issue of 
UNAIDS Science Now. The group plans to examine differences in cause-specific mortality by 
country of origin.   
What are the main strengths and weaknesses?  
COHERE in EuroCoord’s infrastructure is a unique research platform which has prompted 
collaborations both within and beyond Europe. EuroCoord’s cross-network work packages on 
data capture, HIV tuberculosis, migrant health and modelling and its interdisciplinary working 
groups (clinicians, virologists, epidemiologists, biostatisticians) have formalized this cross 
network collaboration and fostered intra-European capacity building. COHERE’s further 
investment in data harmonization (HICDEP) has benefitted other regional collaborations. 
Efforts to streamline data submission with the CASCADE and ART-CC cohort collaborations 
improved efficiency and reduced the workload of DMs. Finally, COHERE has provided 
excellent training opportunities for junior researchers (PhDs and Fellowships). 
COHERE’s greatest strength is its size, enabling stratification of subgroups of interest 8 (e.g. 
across 10 age groups and sex-stratification) and the study of uncommon outcomes.28  The 
robustness of COHERE’s findings transcends Europe, benefiting the global HIV-patient 
community. COHERE data are highly representative of those in care in countries with large 
regional and national cohorts. Such cohorts enable COHERE to monitor trends across 
countries. However, adequate representation of marginalized groups such as migrant 
populations has become a challenge as a consequence of informed consent requirements in 
some countries as well as barriers to accessing care.34  
Although COHERE uses HICDEP, the heterogeneity in data quality remains an ongoing 
challenge. In collaboration with ART-CC 3, COHERE has been an ideal platform for 
harmonizing the collection and validation of causes of deaths in HIV-1 infected individuals. 
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With a growing proportion of deaths now caused by non-AIDS events, accurately monitoring 
causes of death is critical to identify trends and evaluate risk factors. The progressive 
implementation of the “Coding Causes of Death in HIV” Protocol (CoDe), a uniform 
classification system for collecting and validating (via a centralized review process) data on 
causes of death and contributing factors in HIV-1 infected patients, developed by the D:A:D 
collaboration, has become a priority.35  
Despite COHERE’s demonstrated ability to evolve and adapt to respond to new research 
questions, it is now facing the challenge of expanding cohort and clinic-based databases to 
include clinical outcomes that were not initially of interest. As the cohort of PLWH in Europe 
ages, comorbidities, such as cardiovascular, metabolic, neurocognitive, and bone diseases, 
have become increasingly relevant to the study of prognosis in the era of cART. If COHERE 
and its contributing cohorts were formed today, more emphasis would be placed on linking 
HIV databases with other health databases (e.g. cancer registries, hospital or other 
administrative databases, etc.).  
COHERE from a patient’s perspective 
COHERE has maintained close ties with the patient community via its patient representative 
on the COHERE SC. Data from COHERE helped to demonstrate the value of high quality 
treatment strategies and enabled people living with HIV understand the evolving nature of 
the epidemic as well as face the ongoing challenges of growing older with HIV. Findings from 
COHERE have informed and guided the patient community’s discussions with governments 
and authorities about treatment guidelines and standards of care. 
Can I get hold of the data?  Where can I find out more? 
COHERE welcomes applications from Principal Investigators (PIs) of European cohorts 
interested in joining the COHERE collaboration. Interested cohorts must be willing to 
transform their data to fit HICDEP codes and adhere to the data submission timeline laid out 
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in the COHERE Data Management SOP. COHERE DMs hold several explanatory webinars 
covering the data submission process to facilitate data transfer.  
Those interested in using COHERE data to conduct a project can download a COHERE 
Project Proposal Form and a Data Specification Form from our website (www.cohere.org). 
Proposals from external investigators will undergo the same rigorous scrutiny as those from 
investigators within the study group (details outlined in the COHERE Manual of Operations, 
available at www.cohere.org). 
Conclusion 
COHERE is now a mature collaboration, which is unique in its size and coverage. It 
continues to produce new evidence on clinical outcomes, particularly AIDS-defining 
complications, late presentation and socio-economic inequalities, which inform clinical 
guidelines and public health policy recommendations. As PLWH live longer with a chronic 
infection, comparisons between them and cohorts of uninfected individuals are needed to 
disentangle the role of HIV infection from its long-term treatment and comorbidities, 
especially those linked to ageing.  
Profile in a nutshell  
• The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) 
is a project-driven cohort consortium that was set-up to address scientific questions 
that could not be addressed by single cohorts because of sample size requirements.  
• COHERE has grown from 33 cohorts in 2005 to 40 in 2015.  The 2014 merger, 
representing 14 projects, compiled data from 331 481 individuals from 34 European 
countries, including 2808 children (<13), representing 2 135 896 person-years of 
follow-up.  
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• As a consortium of cohorts comprising clinic/hospital-based and interval cohorts, the 
frequency of patient follow-up varies. For clinic or hospital-based cohorts, average 
patient follow-up reflects current standards of care in those countries.  
• COHERE compiles data on clinical characteristics, antiretroviral therapy and other 
medications, estimated date of HIV seroconversion, opportunistic infections, 
laboratory results and socio demographic data according to the requirements of 
projects.  
• External collaborators interested in conducting a project in COHERE should submit a 
project proposal to the Regional Coordinating Centres in Bordeaux and Copenhagen 
for review by COHERE’s governing bodies (see www.cohere.org for further 
information). 
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Box 1: COHERE’s Principles  
• COHERE should neither threaten nor compete with the scientific agendas of participating 
cohorts/cohort collaborations. 
• The individual contributing cohorts must express their interest in participating in COHERE. 
• The scientific questions addressed by COHERE are determined by consensus according to both 
their scientific relevance and originality (not being addressed elsewhere).  
• Individual cohorts may veto the use of their data in any new project.  
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 
 
 Regional Coordinating Centres 
19.99 – 5 % 
≤ 4.99 %  
49.99 – 20 %  
≥ 50 %  
Persons Living with HIV (PLHIV) in COHERE as of 
31/12/2011 as a proportion of 2011 UNAIDS 
estimates of PLHIV per country 
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Cohort Cohort Type Eligibility criteria Beginning of Enrollment End of Enrollment Data Collection N Sites/ Countries Location of sites
AHIVCOS Hospital-based, Surveillance System All HIV+ persons in care at 6/7 national centres 1/1/1996 Prospectively 6 Austria (National)
AMACS Clinic-based, Hospital-based All HIV-1+ persons in at affiliated sites for at least 1 year, alive on 1/1/1996 1/1/1996
Both prospectively and 
retrospectively
13 Greece (Regions : Attiki, Patras, Alexandroupolis)
ANRS CO2 SEROCO Interval cohort
HIV diagnosis <1 year before enrollment or a known date of infection identified by incomplete 
evokative Western-blot or an interval of less than 2 years between a negative and a positive 
ELISA
1/1/1988 12/31/2009 Prospectively 25 France (Paris area, Marseille, Nice)
ANRS CO3 AQUITAINE Hospital-based HIV-1+ >= age 13, seen at least once at a site & signed informed consent 1/1/1987 Prospectively 13 France (Region : Aquitaine) 
ANRS CO4 FHDH Hospital-based HIV-1 or HIV-2+ individuals who have provided written informed consent 1/1/1989 12/31/2065 Prospectively 70 France (National, except Aquitaine)
ANRS CO6 PRIMO Interval cohort HIV 1+ patients presenting during primary infection in sites 1/1/1996 Prospectively 80 France (National)
ANRS CO8 APROCO-COPILOTE Hospital-based HIV-infected patients >= 18 years old, naive for protease inhibitors 1/4/1997 6/6/1999 Prospectively 49 France (National)
ANRS CO13 HEPAVIH Hospital-based
Phase I : [12/2005, 12/2008]: HIV-1/HCV chronically infected >= age 18, 
Phase II : [9/2011, 3/2016]: HIV-1/HCV chronically infected >= age 18,  beginning anti-
HCV treatment comprising Telaprevir or Boceprevir, or having cleared HCV spontaneously 
in the absence of anti-HCV treatment. 
Phase III : [Q1/2014, Q1/2016] : Individuals who have received, are receiving, or will 
receive within the next 6 months combination therapy with new anti-HCV drugs, with or 
without peginterferon and/or ribavirin (temporary authorization, full marketing authorization, 
or within clinical trials) & individuals previously included in ANRS clinical trials 
evaluating new anti-HCV drugs
11/10/2005
Prospectively generally, 
and Prospective & 
Retrospective for Phase 
III
27 France (National)
ATHENA Clinic-based
Any HIV+ person entering care in one of the 27 adult (28 including Curacao) or 4 pediatric 
HIV treatment centers in the Netherlands and who does not object to standardized collection 
of data obtained as part of routine care
1/1/1998
Both prospectively and 
retrospectively
31 The Netherlands, Curacao (National) 
Bonn-Cologne Cohort Clinic-based, Hospital-based HIV+ 1/5/1988
Both prospectively and 
retrospectively
2 Germany (Bonn, Cologne) 
CASCADE Clinic-based, Hospital-based HIV+ with well estimated dates of HIV seroconversion 1/1/1979
Both prospectively and 
retrospectively
 - 11 countries*
Clinserv Clinic-based, Hospital-based All patients HIV+ presenting at the clinical sites after 0/0/1999 1/1/1999
Both prospectively and 
retrospectively
18 Germany
CoRIS Clinic-based
Confirmed HIV+, cART-naive, attending participating sitesl aged >16 & signed informed 
consent 1/1/2004 Prospectively 37 Spain (Multi-region)
CoRIS-MD Clinic-based HIV+ 1/1/1997 12/31/2003 Retrospectively 10 Spain (Multi-region)
DHK Hospital-based HIV+ & in care in HIV treatment centres 1/1/1995 Prospectively 8 Denmark (National)
ECS Clinic-based, Hospital-based
Pregnant HIV+ women, diagnosed before or during pregnancy or as a result of HIV testing 
intrapartum, delivering liveborn infant.
7/15/1985 Prospectively 10 countries 10 countries^
EuroSIDA Clinic-based, Hospital-based, Interval cohort Aged > 16 & prebooked hospital appointment 1/6/1994
Both prospectively and 
retrospectively
109 sites, 34 countries 34 countries^^
Frankfurt Clinic-based HIV+ > age 16 in care at affiliated sites 1/1/1987 Prospectively 5 Germany (Frankfurt)
Gemes Haemo Clinic-based, Surveillance System HIV+ haemophilics infected in early 1980s 5/26/1999 4/26/1999
Both prospectively and 
retrospectively
2 Spain (Madrid, Barcelona)
Georgian National HIV Cohort Clinic-based, Hospital-based, Surveillance System HIV+ adults 1/1/2007
Both prospectively and 
retrospectively
1 Georgia
ICC (INMI Clinical Cohort) Clinic-based, Hospital-based HIV+ individuals in care at site 1/1/1995 Prospectively 1 Italy (Rome)
ICONA Hospital-based HIV+, ART-naive, >= age 18 & signed informed consent 1/1/1997 Prospectively 42 Italy
Infectious Disease Database (IDD) San Raffaele Hospital-based All HIV+ patients in care at site 1/1/1991 Prospectively 1 Italy (Milan)
Italian MASTER Cohort Clinic-based HIV-1 or HIV-2+ (antibody test or positive HIV RNA) in care in participating sites 1/1/1997
Both prospectively and 
retrospectively
8 Italy (multi-city)
Modena Clinic-based
All new HIV diagnosis in adult patients (>= 18 year) since 1985, inhabitant in Province of 
Modena and reffered to Regional Surveillance System. Data were retrospectively collected 
from 1992.
1/1/1992 12/31/2014 Retrospectively 1 Italy (Modena)
PISCIS Clinic-based, Hospital-based
HIV+ >= age 16 in care at one of the sites after January 1st 1998, irrespective of the stage of 
disease or degree of immunosuppression.
1/1/1998
Both prospectively and 
retrospectively
11
Spain (Region : Catalonia)
SHCS Clinic-based, Hospital-based Any HIV+ persons >= age 18 1/1/1988 Prospectively 7 Switzerland (National) 
St Pierre Clinic-based, Hospital-based HIV+ & at least one visit at affiliated sites 1/25/1980 Prospectively 1 Belgium (Brussels)
Swedish InfCare HIV cohort Clinic-based, Hospital-based, Surveillance System All HIV+ persons in care in Sweden, opt out system 1/1/1983
Both prospectively and 
retrospectively
29 Sweden (National)
UK Collaborative HIV Cohort Study (UK CHIC) Clinic-based HIV+ persons > age 16 & <= 1 visit at affilitated site after 1/1/1995 1/1/2001
Both prospectively and 
retrospectively
19 United Kingdom (National)
VACH Hospital-based HIV+ persons > age 16 & 1st visit at affiliated site. 1/1/1997 Prospectively 23 Spain
* Austria, France, Germany, Greece, Italy, Netherlands, Norway, Spain (Badalona, Barcelona, Madrid Valencia), Sweden, Switzerland, United Kingdom
^ Belgium, Denmark, Germany, Netherlands, Poland, Italy, Spain, Sweden, Ukraine, United Kingdom
^^ Argentina, Austria, Belarus, Belgium, Bosnia-Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Georgia, Greece, Hungary, Iceland, Ireland, Israel, Italy, Latvia, Lithuania, Luxembourg,Netherlands, Norway, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Ukraine, United Kingdom) 
Table 1a: Description of the cohort type, eligibility criteria, period of enrolment, and location of data collection of the adult or mixed (adult/paediatric) cohorts participating in COHERE (circa 2015)
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Name of 
Cohort
Cohort Type Eligibility Criteria
Enrolment 
period
Data Collection
N Sites/ 
Countries
Location 
of sites
AALPHI
Clinic & community-
based, Interval cohort
HIV+ age 13-21 and in paediatric 
care in UK, HIV-uninfected age 13-
23, sibling of HIV-infected or has 
HIV+ parent
06/01/2012 -
12/31/2014
Prospectively -
United 
Kingdom 
(Region : 
England) 
ANRS CO10 EPF Interval cohort
HIV+ children included at birth 
(born to HIV-pregnant women 
enrolled in the CO1-EPF cohort), 
or, since 2005, at time of first HIV 
care management in the clinical 
participating sites
09/07/1985 - Prospectively 24 France
CHIPS
Clinic-based, Hospital-
based, Surveillance 
System
All HIV+ children living in the 
UK/Ireland
04/01/2000- Prospectively  - 
United 
Kingdom 
(National), 
Ireland 
(National)
CoRISPE-cat Hospital-based HIV+ <18 years at diagnosis 01/01/2008 -
Both prospectively 
and retrospectively
13
Spain 
(regions : 
Catalonia, 
Balearic 
Islands)
CoRISpeS-Madrid Hospital-based HIV+, infected before age 18 01/01/2002 -
Both prospectively 
and retrospectively
59
Spain 
(national)
KOMPNET 
Children Cohort
Clinic-based HIV+, < 18 age 06/01/2005 -
Both prospectively 
and retrospectively
7
Germany 
(National)
Madrid PMTCT 
Cohort
Hospital-based
HIV-1+ women during pregnnacy 
and their HIV-exposed infants
1/2/0200 Prospectively 7
Spain 
(Madrid)
NENEXP Hospital-based
HIV+ pregnant women & HIV-
exposed children, HAART-exposed 
children until 18 month-old age.
01/01/2000 - Prospectively 12
Spain 
(region: 
Catalonia)
NSHPC Surveillance System
All pregnancies in HIV+ women 
living in the UK or Ireland, their 
exposed infants, and all children 
with HIV infection
01/01/1990 - Prospectively 230
United 
Kingdom & 
Ireland 
(National)
St Pierre 
Paediatric
Hospital-based
All HIV+ children/adolescents in 
care at site
01/01/2000 -
Both prospectively 
and retrospectively
1
Beligum 
(Brussels)
Table 1b: Description of the cohort type, eligibility criteria, period of enrolment, and location of data 
collection of paediatric or adolescent cohorts participating in COHERE (circa 2015)
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AHIVCOS 4676 30505 1247 (27) 34 (28; 42) 3232 (69.1) 1727 (36.9) 1673 (35.8) 1008 (21.6) 88 (1.9) 5 (0.1) 175 (3.7) 3296 (70.5) 4.7 (3.8; 5.3) 3865 (82.7) 354 ( 175; 552)
AMACS 5359 35101 870 (16) 34 (27; 42) 4377 (81.7) 2707 (50.5) 1399 (26.1) 351 (6.5) 101 (1.9) 9 (0.2) 792 (14.8) 3821 (71.3) 4.5 (3.7; 5.1) 4244 (79.2) 348 ( 169; 548)
ANRS CO2 SEROCO 1543 15766 452 (29) 30 (26; 36) 824 (53.4) 711 (46.1) 494 (32.0) 143 (9.3) 92 (6.0) 103 (6.7) 911 (59.0) 4.1 (3.6; 4.7) 1526 (98.9) 480 ( 326; 669)
ANRS CO3 AQUITAINE 8457 63667 2202 (26) 35 (29; 43) 5354 (63.3) 3268 (38.6) 2398 (28.4) 1969 (23.3) 390 (4.6) 29 (0.3) 403 (4.8) 2640 (31.2) 4.3 (3.0; 5.0) 6205 (73.4) 330 ( 155; 516)
ANRS CO4 FHDH 87925 637178 28899 (33) 35 (30; 43) 65261 (74.2) 28609 (32.5) 41088 (46.7) 9090 (10.3) 1560 (1.8) 298 (0.3) 7280 (8.3) 52143 (59.3) 4.4 (3.5; 5.1) 75154 (85.5) 337 ( 175; 520)
ANRS CO6 PRIMO 1563 7997 219 (14) 35 (29; 43) 1522 (97.4) 1101 (70.4) 366 (23.4) 4 (0.3) 1 (0.1) 91 (5.8) 1558 (99.8) 5.2 (4.5; 5.8) 1558 (99.7) 514 ( 370; 666)
ANRS CO8 COPILOTE 1184 8761 280 (24) 36 (32; 43) 873 (73.3) 464 (39.2) 405 (34.2) 194 (16.4) 30 (2.5) 91 (7.7) 1176 (99.3) 4.5 (3.7; 5.2) 1173 (99.1) 273 ( 126; 424)
ANRS CO13 HEPAVIH 1146 4431 325 (28) 46 (42; 49) 805 (70.2) 155 (13.5) 184 (16.1) 688 (60.0) 71 (6.2) 1 (0.1) 47 (4.1) 1076 (93.9) 1.6 (1.6; 1.9) 1071 (93.5) 450 ( 312; 647)
ATHENA 21177 136563 4190 (20) 39 (32; 46) 15667 (74.0) 12323 (58.2) 6434 (30.4) 749 (3.5) 233 (1.1) 32 (0.2) 1406 (6.6) 19806 (93.5) 4.4 (2.6; 4.9) 19736 (93.2) 360 ( 190; 550)
Bonn*** 1978 13125 377 (19) 36 (30; 44) 1512 (76.4) 937 (47.4) 502 (25.4) 200 (10.1) 189 (9.6) 5 (0.3) 145 (7.3) 1270 (64.2) 4.1 (2.6; 4.9) 1653 (83.6) 365 ( 191; 563)
Cologne*** 1742 1951 221 (13) 37 (30; 45) 926 (53.2) 1010 (58.0) 230 (13.2) 142 (8.2) 37 (2.1) 323 (18.5) 573 (32.9) 4.3 (3.1; 5.0) 946 (54.3) 250 ( 50; 490)
CASCADE 9037 66196 1387 (15) 31 (26; 38) 7288 (80.6) 5565 (61.6) 1467 (16.2) 1735 (19.2) 270 (3.0) 2655 (29.4) 4.9 (4.2; 5.6) 4223 (46.7) 514 ( 368; 711)
ClinSurv 17599 98130 3467 (20) 38 (32; 46) 9055 (51.5) 2581 (14.7) 1622 (9.2) 125 (0.7) 38 (0.2) 4178 (23.7) 13904 (79.0) 4.6 (3.8; 5.2) 14201 (80.7) 330 ( 160; 520)
CoRIS*** 6466 19589 1070 (17) 35 (29; 43) 5432 (84.0) 3728 (57.7) 1893 (29.3) 621 (9.6) 224 (3.5) 5504 (85.1) 4.7 (4.0; 5.2) 5553 (85.9) 375 ( 194; 538)
CoRIS-MD*** 3493 14953 990 (28) 35 (31; 39) 2334 (66.8) 492 (14.1) 755 (21.6) 1975 (56.5) 94 (2.7) 177 (5.1) 854 (24.4) 4.5 (3.0; 5.2) 1448 (41.5) 310 ( 140; 527)
DHK 6367 49416 1573 (25) 38 (31; 46) 4776 (75.0) 2894 (45.5) 2409 (37.8) 586 (9.2) 84 (1.3) 8 (0.1) 386 (6.1) 3704 (58.2) 4.6 (3.7; 5.1) 4772 (74.9) 300 ( 120; 500)
ECS 5295 5453 5295 (100) 27 (24; 31) 5074 (95.8) 4736 (89.4) 320 (6.0) 16 (0.3) 223 (4.2) 895 (16.9) 3.9 (2.8; 4.6) 1528 (28.9) 439 ( 301; 604)
EuroSIDA 13384 85203 3854 (29) 36 (30; 43) 8168 (61.0) 4645 (34.7) 4218 (31.5) 3665 (27.4) 169 (1.3) 687 (5.1) 7782 (58.1) 4.0 (2.8; 4.8) 12477 (93.2) 316 ( 165; 486)
GEMES Haemo 94 2210 5 (5) 21 (17; 24) 72 (76.6) 94 (100.0) - - - - 3 (3.2) 130 ( 111; 748)
Infectious Disease Database (IDD) San Raffaele 2870 21618 485 (17) 36 (31; 43) 2397 (83.5) 1257 (43.8) 620 (21.6) 274 (9.5) 8 (0.3) 4 (0.1) 707 (24.6) 2817 (98.15) 4.3 (3.3; 5.0) 2698 (94.0) 420 ( 228; 620)
ICC (INMI Clinical Cohort) 2947 24752 823 ( 28) 37 (31; 43) 2043 (69.3) 595 (20.2) 911 (30.9) 752 (25.5) 31 (1.1) 8 (0.3) 650 (22.1) 1795 (60.9) 4.5 (3.1; 5.2) 2696 (91.5) 315 ( 135; 525)
ICONA 9894 50626 2586 (26) 36 (31; 43) 8882 (89.8) 2913 (29.4) 3933 (39.8) 2436 (24.6) 44 (0.4) 568 (5.7) 8772 (88.7) 4.5 (3.8; 5.1) 9104 (92.0) 401 ( 208; 593)
Italian MASTER Cohort 12728 74753 3458 (27) 37 (31; 44) 9558 (75.1) 2250 (17.7) 5074 (39.9) 2583 (20.3) 62 (0.5) 5 2754 (21.6) 9723 (76.2) 4.6 (3.9; 5.2) 9927 (78.0) 304 ( 122; 511)
Modena 1730 18239 560 (32) 33 (27; 41) 1252 (72.4) 334 (19.3) 732 (42.3) 545 (31.5) 11 (0.6) 1 (0.1) 107 (6.2) 718 (41.5) 4.6 (3.8; 5.3) 907 (52.4) 321 ( 133; 555)
PISCIS 14202 75297 3164 (22) 36 (31; 43) 11054 (77.8) 5105 (35.9) 5340 (37.6) 2481 (17.5) 47 (0.3) 60 (0.4) 1169 (8.2) 9878 (69.6) 4.5 (3.4; 5.2) 10184 (71.7) 312 ( 136; 516)
SHCS 10193 70179 2961 (29) 37 (31; 44) 7957 (78.1) 4106 (40.3) 4197 (41.2) 1000 (9.8) 80 (0.8) 9 (0.1) 801 (7.9) 8028 (78.8) 4.4 (3.3; 5.1) 10147 (99.5) 349 ( 179; 533)
St Pierre 6925 40047 2613 (38) 35 (28; 42) 4909 (70.9) 2158 (31.2) 3834 (55.4) 429 (6.2) 128 (1.8) 53 (0.8) 323 (4.7) 3238 (46.8) 4.5 (3.4; 5.0) 4396 (63.5) 334 ( 169; 528)
UK Collaborative HIV Cohort Study (UK CHIC) 47117 291082 12923 (27) 34 (29; 40) 37616 (79.8) 23208 (49.3) 17178 (36.5) 1690 (3.6) 296 (0.6) 4745 (10.1) 21366 (45.3) 4.4 (3.1; 5.1) 25873 (54.9) 307 ( 140; 488)
VACH 21582 149654 5020 (23) 35 (30; 41) 16205 (75.1) 5914 (27.4) 6504 (30.1) 7089 (32.8) 76 (0.4) 14 (0.1) 1985 (9.2) 9344 (43.3) 4.8 (4.1; 5.3) 10000 (46.3) 308 ( 129; 504)
TOTAL 328,673 2112438 91,516 (28) 35 (30; 43) 235,370 (71.6) 127,231 (38.7) 121,555 (37.0) 44341 (13.5) 3861 (1.2) 875 (0.3) 30,810 (9.4) 199,247 (60.6) 4.5 (3.5; 5.1) 247,268 75 340 ( 170; 530)
* Enrolment : measurements taken in the period six months prior to and one month after the variable “enrolment date”
** Includes a small proportion of MSM+IDU
*** Cohorts who have merged administratively but which represent 'one cohort' insofar as COHERE governance
MSM**
Hetrosexual 
contact
IDU
Blood 
Products
Perinatal 
infected
Unknown
Table 2a : Number of individuals, person-years of follow-up, patient demographics, prior AIDS status, mode of infection, median CD4 cell count and logarithm viral load in individuals older than 13 years old, 
(COHERE, 2014 merger)
Cohort N
Person-
years
Female [N 
(%)]
Median Age 
(IQR)
No AIDS [N, (%)]  
prior to/during 
follow-up
Mode of infection [N (%)]
HIV RNA(log10 
cp/ml) assessment 
at enrolment*, N 
(%)
Median HIV 
RNA (log10 
cp/ml) at 
enrolment* 
(IQR)
CD4 cell count 
assessment at 
enrolment*, N 
(%)
Median CD4 cell 
count at 
enrolment* (IQR)
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ANRS CO10 
EPF
193 1583 112 (58.0) 0 (0; 3) 176 (91.2) 1 (0.5) 188 (97.4) 4 (2.1) 0  - - - 130 (67) 1535 ( 708;2349)
ATHENA** 254 1605 126 (49.6) 5 (3; 8) 204 (80.3) 5 (2.0) 235 ( 92.5) 14 (5.5) 241 (95) 2.5 ( 1.7; 4.8) 241 (95) 1000 ( 620; 1550)
CHIPS 1765 14793 914 (51.8) 4 ( 0.7; 8) 1281 (72.6) 33 (1.9) 1662 (94.2) 70 (4.0) 546 (30) 4.7 ( 4.0; 5.4) 618 (35) 553 (254; 1000)
CORISPE-cat
219 2834 129 (58.9) 1 (0.3; 3) 121 (55.3) 3 (1.4) 200 (91.3) 8 (3.7) 70 (32) 5.4 ( 4.9; 5.9) 79 (36) 1206 ( 464; 2185)
CoRISpeS-
Madrid
318 2514 159 (50.0) 2 (0.3; 5) 237 (74.5) 3 0.9 5 (1.6) 294 ( 92.5) 16 (5.0) 235 (73) 5 ( 4.3; 5.6) 100 (31) 927 ( 358; 1977)
KOMPNET 
Children 
Cohort
59 129 28 (47.5) 8 (4;11) 49 (83.1) 53 (89.8) 6 (10.2) 44 (75) 1.7 ( 1.7; 2.5) 0  - -  -
Total 2808 23,458 1468 (52.3) 3 (0.5; 8) 1953 (73.4) 11 0.4 47 (1.7) 2632 (93.7) 118 (4.2) 1136 (40) 4.6 ( 3.3; 5.4) 1168 (42) 762 ( 366;1425)
Perinatal 
infected
Unknown
* Enrolment : measurements taken in the period six months prior to and one month after the variable “enrolment date”
** Mixed (adult/paediatric) cohorts 
No AIDS [N (%)]
Table 2b : Number of individuals, person-years of follow-up, patient demographics, prior AIDS status, mode of infection, median CD4 cell count and 
logarithm viral load in individuals enrolled in paediatric cohorts or enrolled in mixed cohorts and younger than 13 years old, (COHERE, 2014 merger)
Cohort N
Person-
Years 
Female [N 
(%)]
Median 
Age (IQR)
HIV RNA  
(log10 
cp/ml) 
assessment 
at 
enrolment*, 
N (%)
Median HIV 
RNA values 
(log10 cp/ml) at 
enrolment* 
(IQR)
CD4 cell 
count 
assessment 
at 
enrolment*, 
N (%)
Median CD4 values 
(cells/µl) at 
enrolment* (IQR)Sexual 
Contact
Blood 
products
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Title: Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord 
Authors:  COHERE in EuroCoord (A complete list of the members of the writing committee is available in the full 
version of the profile) 
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Cohort purpose:  The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) was formed 
to pool and harmonize existing longitudinal data on people living with HIV (PLWH) collected across Europe to 
answer key research questions that, in the era of potent combination antiretroviral therapy (cART), could not be 
addressed adequately by individual cohorts. 
Cohort Basics: COHERE has grown from 33 cohorts in 2005 to 40 cohorts as of 2015.  As COHERE is a project-based 
collaboration, the nature of annual mergers depends on the projects included. The 2014 merger compiled data 
from 331 481 individuals from 34 European countries, including 2808 children (<13), representing 2 135 896 
person-years of follow-up.  Approximately a quarter of the COHERE sample is female (27%). The median age at 
inclusion is 35 [IQR: 30, 43]. The primary mode of HIV transmission is sexual contact [homosexual/bisexual contact 
(38.7%), heterosexual contact (37%)], followed by injection drug use (13.5%). Overall, 71.6% of the sample had 
never had a clinical AIDS diagnosis before or during enrolment. 
Follow-up and attrition: As a consortium of cohorts comprising clinic and interval cohorts, patient follow-up varies. 
For clinic or hospital-based cohorts, average patient follow-up reflects current standards of care in those countries.  
Design and Measures: COHERE is a cohort consortium that compiles data from 40 diverse cohorts of PLWH in 
Europe annually. The specific data merged is dictated by the eligibility criteria for included projects.  Data 
categories commonly include clinical characteristics, antiretroviral therapy and other medications, estimated date 
of HIV seroconversion, opportunistic infections, laboratory results and socio demographic data. 
Unique features : The submission of data to COHERE is facilitated by the use of the HIV Cohorts Data Exchange 
Protocol (HICDEP), a flexible data structure, developed in 2004, to guide the mapping of individual cohort data into 
a standard format to facilitate data merging, and the HIV Distributed Data Management Tool (http://www.hiv-
ddm.net/). A series of quality assurance checks are conducted centrally and cohorts address data inconsistencies 
before data are merged. Likely duplicate patient records between and within cohorts are identified using 
probability linkage and reconciled.  
Reasons to be cautious : Although COHERE uses HICDEP, the heterogeneity in data quality remains a challenge. 
With a growing proportion of deaths in PLVH are caused by non-AIDS events, accurately monitoring these causes is 
key to identifying trends and evaluating risk factors.  The “Coding Causes of Death in HIV” Protocol (CoDe), a 
uniform classification system for collecting and validating data on causes of death and contributing factors in HIV-1 
infected patients is being implemented.    
Collaboration and data access : External collaborators interested in conducting a project in COHERE should submit 
a proposal to the Regional Coordinating Centres for review by COHERE’s governing bodies (see www.cohere.org). 
Funding and competing interests : The COHERE has received unrestricted funding from: Agence Nationale de 
Recherches sur le SIDA et les Hépatites Virales (ANRS), France; HIV Monitoring Foundation, The Netherlands; and 
the Augustinus Foundation, Denmark. The research leading to these results has received funding from the 
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European Union Seventh Framework Programme (FP7/2007-2013) under EuroCoord grant agreement n° 260694. 
Participating cohort funders are listed at www.COHERE.org. 
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